CN112142743A - 杂环类化合物、其制备方法及其在医药学上的应用 - Google Patents

杂环类化合物、其制备方法及其在医药学上的应用 Download PDF

Info

Publication number
CN112142743A
CN112142743A CN201910572091.9A CN201910572091A CN112142743A CN 112142743 A CN112142743 A CN 112142743A CN 201910572091 A CN201910572091 A CN 201910572091A CN 112142743 A CN112142743 A CN 112142743A
Authority
CN
China
Prior art keywords
alkyl
mmol
methyl
cycloalkyl
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910572091.9A
Other languages
English (en)
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Innocare Pharma Tech Co ltd
Original Assignee
Nanjing Innocare Pharma Tech Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Innocare Pharma Tech Co ltd filed Critical Nanjing Innocare Pharma Tech Co ltd
Priority to CN201910572091.9A priority Critical patent/CN112142743A/zh
Priority to AU2020301437A priority patent/AU2020301437B2/en
Priority to CA3144799A priority patent/CA3144799A1/en
Priority to TW109121616A priority patent/TWI851747B/zh
Priority to MX2021015969A priority patent/MX2021015969A/es
Priority to BR112021026531A priority patent/BR112021026531A2/pt
Priority to PH1/2021/553257A priority patent/PH12021553257A1/en
Priority to JP2021577587A priority patent/JP7560136B2/ja
Priority to PCT/CN2020/098105 priority patent/WO2020259584A1/en
Priority to KR1020227000934A priority patent/KR102926602B1/ko
Priority to EP20832538.1A priority patent/EP3990449A4/en
Priority to CN202080047732.XA priority patent/CN114096532B/zh
Publication of CN112142743A publication Critical patent/CN112142743A/zh
Priority to US17/559,330 priority patent/US12448382B2/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
CN201910572091.9A 2019-06-28 2019-06-28 杂环类化合物、其制备方法及其在医药学上的应用 Pending CN112142743A (zh)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CN201910572091.9A CN112142743A (zh) 2019-06-28 2019-06-28 杂环类化合物、其制备方法及其在医药学上的应用
JP2021577587A JP7560136B2 (ja) 2019-06-28 2020-06-24 チロシンキナーゼ２活性を仲介する複素環式化合物
PCT/CN2020/098105 WO2020259584A1 (en) 2019-06-28 2020-06-24 Heterocyclic compounds for mediating tyrosine kinase 2 activity
TW109121616A TWI851747B (zh) 2019-06-28 2020-06-24 介導酪氨酸激酶2活性的雜環化合物
MX2021015969A MX2021015969A (es) 2019-06-28 2020-06-24 Compuestos heterocíclicos para mediar la actividad de la tirosina cinasa 2.
BR112021026531A BR112021026531A2 (pt) 2019-06-28 2020-06-24 Composto, composição farmacêutica, e, método para prevenir ou tratar uma doença mediada pela tirosina cinase 2
PH1/2021/553257A PH12021553257A1 (en) 2019-06-28 2020-06-24 Heterocyclic compounds for mediating tyrosine kinase 2 activity
AU2020301437A AU2020301437B2 (en) 2019-06-28 2020-06-24 Heterocyclic compounds for mediating tyrosine kinase 2 activity
CA3144799A CA3144799A1 (en) 2019-06-28 2020-06-24 Heterocyclic compounds for mediating tyrosine kinase 2 activity
KR1020227000934A KR102926602B1 (ko) 2019-06-28 2020-06-24 티로신 키나아제 2 활성을 조정하기 위한 헤테로사이클릭 화합물
EP20832538.1A EP3990449A4 (en) 2019-06-28 2020-06-24 HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY
CN202080047732.XA CN114096532B (zh) 2019-06-28 2020-06-24 抑制酪氨酸激酶2活性的杂环化合物
US17/559,330 US12448382B2 (en) 2019-06-28 2021-12-22 Heterocyclic compounds for mediating tyrosine kinase 2 activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910572091.9A CN112142743A (zh) 2019-06-28 2019-06-28 杂环类化合物、其制备方法及其在医药学上的应用

Publications (1)

Publication Number Publication Date
CN112142743A true CN112142743A (zh) 2020-12-29

Family

ID=73869063

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910572091.9A Pending CN112142743A (zh) 2019-06-28 2019-06-28 杂环类化合物、其制备方法及其在医药学上的应用
CN202080047732.XA Active CN114096532B (zh) 2019-06-28 2020-06-24 抑制酪氨酸激酶2活性的杂环化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080047732.XA Active CN114096532B (zh) 2019-06-28 2020-06-24 抑制酪氨酸激酶2活性的杂环化合物

Country Status (12)

Country Link
US (1) US12448382B2 (https=)
EP (1) EP3990449A4 (https=)
JP (1) JP7560136B2 (https=)
KR (1) KR102926602B1 (https=)
CN (2) CN112142743A (https=)
AU (1) AU2020301437B2 (https=)
BR (1) BR112021026531A2 (https=)
CA (1) CA3144799A1 (https=)
MX (1) MX2021015969A (https=)
PH (1) PH12021553257A1 (https=)
TW (1) TWI851747B (https=)
WO (1) WO2020259584A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113234081A (zh) * 2021-05-27 2021-08-10 东南大学 一种吡咯并吡唑衍生物与dmpeda做脲的制备方法
CN114096532A (zh) * 2019-06-28 2022-02-25 广州诺诚健华医药科技有限公司 抑制酪氨酸激酶2活性的杂环化合物
WO2025124465A1 (en) * 2023-12-15 2025-06-19 Beijing Innocare Pharma Tech Co., Ltd. Method for treating atopic dermatitis

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI782599B (zh) * 2020-07-02 2022-11-01 美商輝瑞股份有限公司 胺基嘧啶基衍生物
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２分解剤およびそれらの使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011328237A1 (en) * 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
US9586962B2 (en) * 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
EP2832734A4 (en) * 2012-03-28 2015-08-26 Takeda Pharmaceutical HETEROCYCLIC COMPOUND
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
CN108137559B (zh) 2015-07-09 2021-11-02 默克专利有限公司 用作btk抑制剂的嘧啶衍生物及其用途
US11649251B2 (en) * 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
CN112142743A (zh) * 2019-06-28 2020-12-29 广州诺诚健华医药科技有限公司 杂环类化合物、其制备方法及其在医药学上的应用

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114096532A (zh) * 2019-06-28 2022-02-25 广州诺诚健华医药科技有限公司 抑制酪氨酸激酶2活性的杂环化合物
CN114096532B (zh) * 2019-06-28 2023-12-01 广州诺诚健华医药科技有限公司 抑制酪氨酸激酶2活性的杂环化合物
US12448382B2 (en) 2019-06-28 2025-10-21 Guangzhou Innocare Pharma Tech Co. Ltd. Heterocyclic compounds for mediating tyrosine kinase 2 activity
CN113234081A (zh) * 2021-05-27 2021-08-10 东南大学 一种吡咯并吡唑衍生物与dmpeda做脲的制备方法
WO2025124465A1 (en) * 2023-12-15 2025-06-19 Beijing Innocare Pharma Tech Co., Ltd. Method for treating atopic dermatitis

Also Published As

Publication number Publication date
EP3990449A4 (en) 2023-07-26
WO2020259584A1 (en) 2020-12-30
CN114096532A (zh) 2022-02-25
KR102926602B1 (ko) 2026-02-11
CA3144799A1 (en) 2020-12-30
TWI851747B (zh) 2024-08-11
TW202115034A (zh) 2021-04-16
JP2022540353A (ja) 2022-09-15
EP3990449A1 (en) 2022-05-04
US20220112200A1 (en) 2022-04-14
JP7560136B2 (ja) 2024-10-02
BR112021026531A2 (pt) 2022-02-15
PH12021553257A1 (en) 2022-08-08
US12448382B2 (en) 2025-10-21
CN114096532B (zh) 2023-12-01
KR20220042344A (ko) 2022-04-05
MX2021015969A (es) 2022-04-18
AU2020301437A1 (en) 2022-02-17
AU2020301437B2 (en) 2026-02-26

Similar Documents

Publication Publication Date Title
CN106061973B (zh) 吡咯并[2,3-d]嘧啶基、吡咯并[2,3-b]吡嗪基和吡咯并[2,3-d]吡啶基丙烯酰胺
JP7560136B2 (ja) チロシンキナーゼ２活性を仲介する複素環式化合物
CN115590854A (zh) 哒嗪基噻唑甲酰胺类化合物
US8637529B2 (en) Pyrazolo[3,4-d]pyrimidine compounds
CN110818641B (zh) 哒嗪-3-甲酰胺类化合物、其制备方法及其在医药学上的应用
CN118772176A (zh) 一种嘧啶并芳环化合物及其制备方法和用途
WO2023241684A1 (zh) Pde4b抑制剂
CN111050765A (zh) 螺环化合物及其制造和使用方法
CN114302886A (zh) 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
JP2025500886A (ja) 大環状ｂｔｋ阻害剤
WO2022032484A1 (zh) 哒嗪-3-甲酰胺类化合物、其制备方法及其在医药学上的应用
CN113429427A (zh) 杂环化合物及其制备方法和药物用途
CN114644633B (zh) 杂环类jak抑制剂
KR20250048005A (ko) 타이로신 키나제 2 저해제 및 이의 용도
RU2826012C2 (ru) Гетероциклические соединения для опосредования активности тирозинкиназы 2
HK40068398B (zh) 抑制酪氨酸激酶2活性的杂环化合物
HK40068398A (en) Heterocyclic compounds for mediating tyrosine kinase 2 activity
CN114315838A (zh) 嘧啶并吡咯类化合物
US20260116887A1 (en) Heterocyclic compounds for mediating tyrosine kinase 2 activity
WO2024061118A1 (zh) 大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用
HK40085586B (zh) 哒嗪基噻唑甲酰胺类化合物
HK40084227B (zh) 哒嗪基噻唑甲醯胺类化合物
HK40059656B (zh) 哒嗪基噻唑甲酰胺类化合物
HK1228913B (zh) 吡咯并[2，3-d]嘧啶基、吡咯并[2，3-b]吡嗪基和吡咯并[2，3-d]吡啶基丙烯酰胺
HK1241857B (zh) 作为jak抑制剂的氨基嘧啶基化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201229

WD01 Invention patent application deemed withdrawn after publication